Kijima Yasufumi, Akagi Teiji, Nakagawa Koji, Taniguchi Manabu, Ueoka Akira, Deguchi Kentaro, Toh Norihisa, Oe Hiroki, Kusano Kengo, Sano Shunji, Ito Hiroshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Cardiovasc Interv Ther. 2014 Jan;29(1):11-7. doi: 10.1007/s12928-013-0193-9. Epub 2013 Jul 4.
Although numerous studies have shown an association between a patent foramen ovale (PFO) and cryptogenic cerebrovascular accidents (CVA), there has been no definitive control study that demonstrated the benefit of percutaneous device closure of a PFO compared to medical therapy in patients with CVA. Additionally, few clinical data exist for Japanese patients in this field. We demonstrate the initial experiences in catheter closure of a PFO as secondary prevention of CVA in Japan. Catheter closure of a PFO was attempted in 7 patients who were diagnosed with cryptogenic CVA. Mean age at the procedure was 54 ± 19 years. The presence of spontaneous interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography without Valsalva maneuver in all of the patients. Amplatzer Cribriform device (n = 4) or Amplatzer PFO Occluder (n = 3) was used for the procedure and was successfully deployed. Device-related complications were not observed at the time of the procedure or during the follow-up period (mean period of 16 ± 9 months). Catheter closure of a PFO could be safely performed with Amplatzer Cribriform or Amplatzer PFO Occluder. This procedure may contribute to prevention of recurrent cryptogenic CVA in Japanese patients.
尽管众多研究已表明卵圆孔未闭(PFO)与隐源性脑血管意外(CVA)之间存在关联,但尚无确凿的对照研究表明,在CVA患者中,经皮封堵PFO相较于药物治疗具有益处。此外,该领域针对日本患者的临床数据较少。我们展示了在日本将PFO导管封堵作为CVA二级预防的初步经验。对7例被诊断为隐源性CVA的患者尝试进行PFO导管封堵。手术时的平均年龄为54±19岁。所有患者经食管对比超声心动图在未行Valsalva动作的情况下均显示存在自发性心房右向左分流。手术采用了Amplatzer筛状封堵器(n = 4)或Amplatzer PFO封堵器(n = 3),且成功植入。手术时及随访期间(平均16±9个月)均未观察到与器械相关的并发症。使用Amplatzer筛状封堵器或Amplatzer PFO封堵器可安全地进行PFO导管封堵。该手术可能有助于预防日本患者复发性隐源性CVA。